We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

91 hedge funds and large institutions have $174M invested in Antares Pharma, Inc. in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $609K

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

15% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 26

2% more funds holding

Funds holding: 89 → 91 (+2)

22% less capital invested

Capital invested by funds: $223M → $174M (-$49M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
91
Holders Change
+2
Holders Change %
+2.25%
% of All Funds
2.63%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
30
Reduced
26
Closed
12
Calls
$1.03M
Puts
$609K
Net Calls
+$425K
Net Calls Change
+$28K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$6.66M
2
JGC
J. Goldman & Co
New York
+$3.15M
3
PI
Putnam Investments
Massachusetts
+$2.6M
4
PWAM
Park West Asset Management
California
+$2.22M
5
MIG
Mariner Investment Group
New York
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$6.11M
2
TAM
THB Asset Management
Connecticut
-$3.94M
3
DM
Deerfield Management
New York
-$2.9M
4
HCM
Harvey Capital Management
Florida
-$2.39M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$33.2M -$2.9M -652,713 -6%
BIT
2
BlackRock Institutional Trust
California
$14.2M +$1.17M +263,004 +7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$13.2M +$934K +210,617 +6%
O
4
OrbiMed
New York
$11.2M -$6.11M -1,378,100 -30%
BFA
5
BlackRock Fund Advisors
California
$11.1M +$419K +94,523 +3%
BC
6
Broadfin Capital
New York
$8.05M +$6.66M +1,500,000 +188%
Millennium Management
7
Millennium Management
New York
$7.86M +$458K +103,217 +5%
State Street
8
State Street
Massachusetts
$7.01M +$20.5K +4,619 +0.2%
Allianz Asset Management
9
Allianz Asset Management
Germany
$6.42M +$586K +132,080 +8%
WHI
10
William Harris Investors
Illinois
$5.3M -$1.26M -285,000 -16%
KCM
11
Kingdon Capital Management
New York
$5.2M -$1.39M -313,362 -17%
Northern Trust
12
Northern Trust
Illinois
$5.14M -$593K -133,589 -8%
UBS AM
13
UBS AM
Illinois
$3.95M +$1.12M +253,300 +29%
PI
14
Putnam Investments
Massachusetts
$3.75M +$2.6M +587,044 +121%
JGC
15
J. Goldman & Co
New York
$3.41M +$3.15M +711,072 +271%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$3.23M +$439K +98,979 +12%
ACM
17
Ashford Capital Management
Delaware
$3.01M +$50.7K +11,425 +1%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.22M +$52.3K +11,796 +2%
PWAM
19
Park West Asset Management
California
$1.75M +$2.22M +500,000 New
TCIM
20
TIAA CREF Investment Management
New York
$1.53M -$77.6K -17,490 -4%
AC
21
Avenir Corporation
Virginia
$1.19M +$7.32K +1,650 +0.5%
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$1.18M – – –
CCM
23
Cadence Capital Management
Massachusetts
$1.18M +$258K +58,082 +21%
BIM
24
BlackRock Investment Management
Delaware
$1.09M +$13.4K +3,029 +1%
MIG
25
Mariner Investment Group
New York
$1.04M +$1.32M +296,477 New
1
2 3 4 5

ATRS Hedge Fund Activity: Q1 2014 in Review

91 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2014, worth a combined $174M — down 22% from $223M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ATRS positions and 12 closed out — a net gain of 2 holders — while 30 added to existing stakes and 26 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $6.66M. The largest seller was OrbiMed, cutting an estimated $6.11M.

  • 91 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2014, up from 89 in Q4 2013.
  • Funds reported $174M of Antares Pharma, Inc. stock for Q1 2014, down 22% quarter-over-quarter.
  • 14 funds opened new Antares Pharma, Inc. positions in Q1 2014 and 12 closed out, a net change of +2 holders.
  • The largest Antares Pharma, Inc. buyer in Q1 2014 was Broadfin Capital, an estimated $6.66M added.
  • The largest Antares Pharma, Inc. seller in Q1 2014 was OrbiMed, an estimated $6.11M sold.

Based on aggregated 13F filings for Q1 2014.